Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 27-Mar-24 5:47 PM View:  | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 25-Mar-24 | Option Exercise | 16,015 | $57.39 | $919,147.00 | 15% 104.14K to 120.16K | |
| 06-Mar-24 10:00 PM View: | Aryeh Jason Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Exercise | 2,893 | $39.35 | $113,840.00 | 2% 128.15K to 131.04K | |
| 07-Mar-24 1:27 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Exercise | 2,893 | -- | -- | 10% 27.93K to 30.82K | |
| 07-Mar-24 1:27 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Sale | 1,893 | $74.30 | $140,650.00 | (6%) 30.82K to 28.93K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Feb-24 | Option Exercise | 1,264 | $56.62 | $71,564.30 | 4% 28.63K to 29.89K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Feb-24 | Option Sale | 140 | $88.46 | $12,384.40 | (< 1%) 29.89K to 29.75K | |
| 29-Feb-24 6:50 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 14,416 | -- | -- | 16% 89.44K to 103.86K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 7,208 | -- | -- | 34% 21.42K to 28.63K | |
| 29-Feb-24 6:50 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 7,208 | -- | -- | 48% 15.0K to 22.2K | |
| 29-Feb-24 6:49 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 32,436 | -- | -- | 45% 71.71K to 104.14K | |
| 16-Feb-24 8:10 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 1,381 | $74.65 | $103,092.00 | (2%) 73.09K to 71.71K | |
| 16-Feb-24 8:10 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 4,778 | $74.65 | $356,678.00 | (5%) 94.22K to 89.44K | |
| 16-Feb-24 8:10 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 1,479 | $74.65 | $110,407.00 | (6%) 22.9K to 21.42K | |
| 16-Feb-24 8:10 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 593 | $74.65 | $44,267.40 | (4%) 15.59K to 15.0K | |
| 04-Jan-24 4:07 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 02-Jan-24 | Payment of Exercise | 2,917 | $72.31 | $210,928.00 | (3%) 97.14K to 94.22K | |
| 04-Jan-24 4:07 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 29-Dec-23 | Acquisition (other) | 179 | $60.71 | $10,866.60 | 1% 15.41K to 15.59K | |
| 06-Dec-23 3:27 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 05-Dec-23 | Payment of Exercise | 1,269 | $59.61 | $75,645.10 | (5%) 24.17K to 22.9K | |
| 06-Dec-23 3:27 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 05-Dec-23 | Payment of Exercise | 1,984 | $59.61 | $118,266.00 | (2%) 99.12K to 97.14K | |
| 03-Oct-23 4:36 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 01-Oct-23 | Payment of Exercise | 346 | $59.92 | $20,732.30 | (1%) 24.52K to 24.17K | |
| 26-Sep-23 4:41 PM View: | Zimmermann Martine Director | Ligand Pharmaceuticals Inc. (LGND) | 22-Sep-23 | Grant | 2,285 | -- | -- | 100% 0 to 2.29K | |
| 25-Sep-23 4:44 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 22-Sep-23 | Private Purchase | 4,000 | $59.38 | $237,529.00 | 6% 69.09K to 73.09K | |
| 14-Aug-23 4:20 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 10-Aug-23 | Payment of Exercise | 897 | $68.73 | $61,650.80 | (6%) 16.31K to 15.41K | |
| 10-Jul-23 6:42 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 30-Jun-23 | Acquisition (other) | 376 | $56.78 | $21,349.30 | < 1% 98.75K to 99.12K | |
| 10-Jul-23 6:42 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 30-Jun-23 | Acquisition (other) | 375 | $56.78 | $21,292.50 | 2% 24.14K to 24.52K | |
| 13-Jun-23 10:00 PM View: | Aryeh Jason Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | < 1% 127.01K to 128.15K | |
| 13-Jun-23 10:00 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Payment of Exercise | 420 | $73.76 | $30,979.20 | (< 1%) 69.51K to 69.09K | |
| 13-Jun-23 10:00 PM View: | Haas Jason Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | 38% 3.0K to 4.14K | |
| 13-Jun-23 10:00 PM View: | Lamattina John L Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | 4% 27.12K to 28.26K | |
| 21-Jun-23 9:28 AM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | 4% 25.78K to 26.93K | |
| 13-Jun-23 10:00 PM View: | Kozarich John W Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | 3% 38.49K to 39.63K | |
| 13-Jun-23 10:00 PM View: | Gray Nancy Ryan Director | Ligand Pharmaceuticals Inc. (LGND) | 09-Jun-23 | Grant | 1,142 | -- | -- | 21% 5.42K to 6.57K | |
| 18-May-23 5:18 PM View: | Kozarich John W Director | Ligand Pharmaceuticals Inc. (LGND) | 16-May-23 | Sale | 4,444 | $77.20 | $343,081.00 | (10%) 42.93K to 38.49K | |
| 12-May-23 3:43 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 10-May-23 | Option Sale | 6,408 | $77.13 | $494,225.00 | (20%) 32.19K to 25.78K | |
| 12-May-23 3:43 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 10-May-23 | Option Exercise | 6,408 | -- | -- | 25% 25.78K to 32.19K | |
| 10-May-23 7:15 PM View: | Kozarich John W Director | Ligand Pharmaceuticals Inc. (LGND) | 08-May-23 | Option Sale | 6,408 | $76.56 | $490,628.00 | (13%) 48.62K to 42.21K | |
| 10-May-23 7:15 PM View: | Kozarich John W Director | Ligand Pharmaceuticals Inc. (LGND) | 08-May-23 | Option Exercise | 6,408 | $18.82 | $120,599.00 | 15% 42.21K to 48.62K | |
| 28-Mar-23 5:00 PM View: | Reardon Andrew See Remarks | Ligand Pharmaceuticals Inc. (LGND) | 24-Mar-23 | Sale | 300 | $69.92 | $20,977.30 | (2%) 16.61K to 16.31K | |
| 27-Feb-23 8:51 PM View: | Reardon Andrew See Remarks | Ligand Pharmaceuticals Inc. (LGND) | 23-Feb-23 | Grant | 5,668 | -- | -- | 52% 10.94K to 16.61K | |
| 27-Feb-23 8:54 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 23-Feb-23 | Grant | 6,046 | -- | -- | 33% 18.1K to 24.14K | |
| 27-Feb-23 8:50 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 23-Feb-23 | Grant | 17,005 | -- | -- | 33% 51.79K to 68.79K | |
| 27-Feb-23 8:52 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 23-Feb-23 | Grant | 9,069 | -- | -- | 10% 89.68K to 98.75K | |
| 17-Feb-23 7:20 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-23 | Payment of Exercise | 849 | $72.98 | $61,960.00 | (4%) 18.95K to 18.1K | |
| 17-Feb-23 7:23 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-23 | Payment of Exercise | 2,890 | $72.98 | $210,912.00 | (3%) 92.57K to 89.68K | |
| 04-Jan-23 5:00 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 30-Dec-22 | Acquisition (other) | 275 | $56.78 | $15,614.50 | 1% 18.67K to 18.95K | |
| 30-Dec-22 5:00 PM View: | Higgins John L Director | Ligand Pharmaceuticals Inc. (LGND) | 28-Dec-22 | Payment of Exercise | 5,289 | $66.29 | $350,608.00 | (1%) 422.98K to 417.69K | |
| 30-Dec-22 5:00 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 28-Dec-22 | Payment of Exercise | 3,859 | $66.29 | $255,813.00 | (4%) 96.43K to 92.57K | |
| 20-Dec-22 6:36 PM View: | Higgins John L Director | Ligand Pharmaceuticals Inc. (LGND) | 16-Dec-22 | Sale (Planned) | 10,000 | $61.87 | $618,657.00 | (2%) 432.98K to 422.98K | |
| 15-Dec-22 6:13 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 13-Dec-22 | Grant | 11,000 | -- | -- | 143% 7.67K to 18.67K | |
| 15-Dec-22 6:17 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 13-Dec-22 | Grant | 14,000 | -- | -- | 17% 82.43K to 96.43K | |
| 14-Dec-22 5:00 PM View: | Higgins John L Director | Ligand Pharmaceuticals Inc. (LGND) | 12-Dec-22 | Option Exercise | 20,000 | $12.78 | $255,600.00 | 5% 416.93K to 436.93K |
